multiple myeloma therapeutics in asia-pacific markets to 2021

www.MarketResearchReports.com

Multiple Myeloma Therapeutics in

Asia-Pacific Markets to 2021 -

Growth Driven by Rising Prevalence,

Continued Success of Velcade, Revlimid and

Emerging Supplementary

Treatments

Category : Pharma & Healthcare

All logos and Images mentioned on this slide belong to their respective owners.


Introduction to Report

Launch Date: October 1, 2015

Number of Pages: 117

Geography Coverage: Asia Pacific

Available Format: PDF

Price For Single User License: USD 4,995

Price For Site User License: USD 9,990

Price For Global User License: USD 14,985

Delivery Time: Within 24 Hours (During Working Days)


About the Report

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments report provides analysis of the multiple myeloma therapeutics space across the Asia-Pacific (APAC) countries of India, China, Australia and Japan, with annualized market data from 2014 and forecast to 2021.

Key topics covered include treatment usage patterns, annual therapy costs, and market growth projections for multiple myeloma treatment in the APAC region.


Key Highlights:

The treatment market for multiple myeloma across the Asia-Pacific (APAC) countries of China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 7.4%, according to new report.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology.

MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.


Key Highlights Continues… Without any treatment, the median survival of a

myeloma patient is about six months, but this can be extended with the use of various forms of treatment. There are now five classes of drugs used in the treatment of myeloma: immunomodulatory drugs, chemotherapy, proteasome drugs, Histone Deacetylase (HDAC) inhibitors and steroids.

Many of the notable drugs in these classes were approved over the past 10–15 years. Treatment using these novel drugs and high-dose chemotherapy with hematopoietic Stem-Cell Transplant (SCT) has been shown to improve median survival to five years, which makes this the current standard therapy.

However, many patients suffer relapse or develop treatment resistance, leaving a need to develop safe and effective treatments that prolong the duration of remission and improve survival.


Reasons to Buy: Understand the clinical context of MM by considering

symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.

Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

Appreciate key pipeline trends in molecule type, administration route, mechanism of action, and novelty.

Consider market opportunities and potential risks by examining trends in clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.


Reasons to Buy Continues… Recognize the late-stage pipeline molecules that have

demonstrated strong therapeutic potential by examining clinical trial data and multi-scenario product forecast projections.

Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia and Japan.

Discover trends in licensing and co-development deals concerning MM products and identify the major strategic consolidations that have shaped the commercial landscape.


Report Coverage:

1. Introduction

2. Marketed Products

3. Pipeline Products

4. Market Forecast to 2021

5. Drivers and Barriers for the Disease Market

6. Deals and Strategic Consolidations

7. Appendix

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.


Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

http://www.marketresearchreports.com/idea-center

http://www.marketresearchreports.com/subscribe-to-newsletter

http://www.marketresearchreports.com/subscribe-to-newsletter


How To Buy This Report?Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/oXg

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)

http://mrr.cm/oXg

http://mrr.cm/oXg

mailto:[email protected]